In a significant development, Robert F. Kennedy Jr. has been confirmed as the Secretary of the U.S. Department of Health and Human Services (HHS) following a closely watched Senate vote. On February 14, 2025, the Senate voted 52-48 to confirm Kennedy, with all Democrats and one Republican, Sen. Mitch McConnell of Kentucky, voting against his confirmation. McConnell's opposition was rooted in Kennedy's long history of spreading conspiracy theories, particularly about vaccines, which McConnell, a polio survivor, strongly opposes[2][4].
Kennedy's confirmation sets the stage for substantial changes within HHS, aligning with his "Make America Healthy Again" agenda. He has pledged to promote healthier foods, tackle pollution, address the root causes of chronic diseases, and ban prescription drug ads. However, his tenure is expected to be contentious, given his controversial views on vaccines and other health issues[2][4].
Concurrent with Kennedy's confirmation, the Trump administration has initiated a major restructuring of the federal workforce, including significant cuts at HHS. An executive order signed by President Trump aims to drastically reduce the federal workforce, and as part of this effort, HHS is set to terminate the employment of nearly all its probationary employees. This move affects approximately 5,200 probationary staff members across HHS, including about 1,300 at the Centers for Disease Control and Prevention (CDC), which is roughly one-tenth of the CDC's workforce. Some probationary employees with specialized skills may be spared, but the majority are expected to receive termination notices. Affected employees will receive four weeks of paid administrative leave[1][5].
The restructuring and layoffs are part of a broader effort by the Trump administration to streamline the federal government and ensure that HHS operates more efficiently. HHS officials have stated that these actions are intended to support the President's goals of restructuring and streamlining the federal government to better serve the American people[1].
In addition to these personnel changes, Kennedy will oversee a range of critical health policy issues, including compliance with clinical trial diversity guidance, ensuring healthcare access, and managing the administration's policies on drug pricing and pharmacy benefit managers. His leadership at HHS is anticipated to bring significant changes and will be closely monitored by both supporters and critics[2][4].